Echo Therapeutics to Present at OneMedForum 2010 Emerging Company Finance Conference

Jan 07, 2010, 07:00 ET from Echo Therapeutics, Inc.

FRANKLIN, Mass., Jan. 7 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that Patrick T. Mooney, M.D., Chairman and Chief Executive Officer, will present at the OneMedPlace Finance Forum 2010 at 11.45 a.m. (PT) on Wednesday, January 13, 2010 at The Sir Francis Drake Hotel in San Francisco, CA.

Company management will be available for one-on-one meetings on January 12th and 13th. Please contact Brett Maas at (646) 536-7331 or brett@haydenir.com to request a meeting.

"Building on the significant positive momentum of 2009, we believe that we have set the stage for an exciting and productive 2010, as we enter the year with most of the initial product development work behind us and two significant strategic partnerships in place," commented Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics. "We are now focused on completing milestone events, including key clinical trials, which will enable us to begin generating revenue. We anticipate near-term revenue for Echo from the royalties on Prelude disposables and lidocaine sales by Ferndale Pharma Group in the topical anesthetic market in the US and UK during 2010. Additionally, we are positioned to be 'first-to-market' with tCGM in the hospital critical care market and we estimate that the hospital market opportunity for continuous glucose monitoring is greater than $1 billion. Finally, we plan to develop our Symphony system for use in the consumer market, providing additional upside potential and partnership possibilities in this more than $10 billion market opportunity. We are excited to share our vision and discuss our future opportunities with investors at this conference."

About the OneMedForum 2010

Held annually in San Francisco, the OneMedPlace Finance Forum was created to connect emerging healthcare and life science companies with investors and strategic partners. Over 100 company presentations will occur by some of the most promising - and typically least recognized - companies in the world. Recognizing the impacts and opportunities connected to healthcare reform and the stimulus package, the conference has added a third day dedicated to Health Information.

More information is available at http://www.onemedplace.com/onemedforum/index.php.

About Echo Therapeutics

Echo Therapeutics is focused on medical devices and specialty pharmaceuticals. Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the efficacy of Echo's Symphony tCGM System and Prelude SkinPrep System, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM System and Prelude SkinPrep System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM System and Prelude SkinPrep System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM System and its Prelude SkinPrep System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2008, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.

www.echotx.com

© 2002 - 2009 Echo Therapeutics, Inc. All rights reserved worldwide.

SOURCE Echo Therapeutics, Inc.



RELATED LINKS

http://www.echotx.com